Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 March 2022 | Story Lacea Loader

On 14 March 2022, the Bloemfontein and Qwaqwa Campuses of the University of the Free State (UFS) will return to face-to-face classes as per the teaching plans for 2022. The faculties that are continuing with face-to-face classes in the first term (i.e., the Faculties of Natural and Agricultural Sciences and Health Sciences), will remain face-to-face during the week of 7 to 11 March 2022.

The decision to resume face-to-face classes follows previous communiques in February 2022 about the temporary closure of the Qwaqwa Campus due to violent protest action, and the continuation of the academic programme on the Bloemfontein Campus in a differentiated and flexible online delivery mode due to challenges experienced with disruption of classes. 
 
The return to face-to-face classes on 14 March 2022 also follows the reopening of and resumption of online classes on the Qwaqwa Campus on 28 February 2022, and the resumption of some face-to-face activity on the Qwaqwa Campus as from 7 March 2022.

As a residential institution, it is important for students to return to campus, for the academic programme to continue as planned, and for activities to return to normal.
 
Students will be informed by their respective faculties as to how the academic programme will be adapted for face-to-face classes, including instances where classes will remain online.

News Archive

Newly operational sequencing unit in genomics at UFS
2016-09-09

Description: Next Generation Sequencing  Tags: Next Generation Sequencing

Dr Martin Nyaga and his research assistant,
Tshidiso Mogotsi in the Next Generation
Sequencing Laboratory.
Photo: Charl Devenish

The Next Generation Sequencing (NGS) unit at the UFS was established as an interdisciplinary facility under the Directorate for Research Development, Faculty of Health Sciences and Faculty of Natural and Agricultural Sciences.

The aim of the NGS facility is to aid internal and external investigators undertaking studies on Deoxyribonucleic acid (DNA) sequencing, assembly and bioinformatics approaches using the more advanced Illumina MiSeq NGS platform.

The NGS unit became operational in 2016 and is managed by Dr Martin Nyaga and administered through the office of the Dean, Faculty of Health Sciences, under the leadership of Prof Gert Van Zyl. Dr Nyaga has vast experience in microbial genomics, having done his PhD in Molecular Virology.

He has worked and collaborated with globally recognised centres of excellence in Prokaryotic and Eukaryotic genomics, namely the J. Craig Venter Institute and the Laboratory of Viral Metagenomics, Rega Institute, among others.

The unit has undertaken several projects and successfully generated data on bacterial, viral and human genomes. Currently, work is ongoing on bacterial and fungal metagenomics studies through 16S rRNA sequencing.

In addition, the unit is also working on plasmid/insert sequencing and whole genome sequencing of animal and human rotaviruses. The unit has capacity to undertake other kinds of panels like the HLA, Pan-cancer and Tumor 15 sequencing, among others.

Several investigators from the UFS including but not limited to Prof Felicity Burt, Prof Wijnand Swart, Dr Frans O’Neil, Dr Trudi O'Neill, Dr Charlotte Boucher, Dr Marieka Gryzenhout and Dr Kamaldeen Baba are actively in collaboration with the NGS unit.

The unit has also invested in other specialised equipment such as the M220 Focused-ultrasonicator (Covaris), 2100 Bioanalyzer system (Agilent) and the real-time PCR cycler, the Rotor-Gene Q (Qiagen), which both the UFS and external investigators can use for their research.

Investigators working on molecular and related studies are encouraged to engage with Dr Nyaga on how they would like to approach their genomics projects at the UFS NGS unit. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept